Fig. 2From: Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetesMean ambulatory systolic and diastolic blood pressures were recorded at weekly intervals during the light a and dark b cycles. Compared to CkC, both DbC and DbE exhibited a mild elevation in blood pressure (P < 0.05), especially during the light cycle and tended to have impaired blood pressure dipping (c), neither of which was affected by empagliflozin treatment. *P < 0.05DbC vs CkC and §P < 0.05 DbE vs CkCBack to article page